Bluebird Bio traded at $1.26 this Tuesday April 9th, increasing $0.10 or 8.62 percent since the previous trading session. Looking back, over the last four weeks, Bluebird Bio gained 9.35 percent. Over the last 12 months, its price fell by 57.14 percent. Looking ahead, we forecast Bluebird Bio to be priced at 1.23 by the end of this quarter and at 1.16 in one year, according to Trading Economics global macro models projections and analysts expectations.
bluebird bio, Inc. is a biotechnology company. The Company focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. It develops LentiGlobin for sickle cell disease (SCD) as a one-time treatment for patients with SCD, a hereditary blood disorder resulting from a mutation in the ß-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. It builds an integrated product platform with therapeutic in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. Its programs in genetic disease include betibeglogene autotemcel; LentiGlobin gene therapy for sickle cell disease (SCD); and elivaldogene autotemcel. Its programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies.